𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma

✍ Scribed by Richard R. Furman; Peter Martin; Jia Ruan; Ying-Kuen K. Cheung; Julie M. Vose; Ann S. LaCasce; Rebecca Elstrom; Morton Coleman; John P. Leonard

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
169 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase 2 trial of fludarabine and mitox
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
✍ Pier Luigi Zinzani; Monica Tani; Stefano Fanti; Vittorio Stefoni; Gerardo Musura πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 101 KB πŸ‘ 1 views

## Abstract ## BACKGROUND A prospective, single‐arm, open‐label, nonrandomized Phase 2 study of combined fludarabine and mitoxantrone (FM) plus radioimmunotherapy was conducted to evaluate efficacy and safety in patients with untreated, indolent, nonfollicular non‐Hodgkin lymphoma (NHL). ## METHO

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day Γ— 3) with mesna (400 mg/m^2^ intravenously q 4 h daily Γ— 3) was combined with mitoxantrone (14 mg/m^2^ intravenously Γ— 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients